NeurogesX, Inc. (Nasdaq: NGSX) today reported results for its third quarter ended September 30, 2010.
Total revenue for the three months ended September 30, 2010 was $2.1 million which consisted of $1.9 million in collaboration...(read more
Possible take over canidates and really do your dd. I cannot offer investment advice. I can only offer Tips. My work day never stops for the benefit of members.
NeurogesX Inc...(read more
NeurogesX (NGSX) received some very good news this week when the U.S. FDA approved Qutenza for the management of postherpetic neuralgia (PHN). Management will now move forward with preparing for the...(read more